



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

図 2.7.3.6-31　前治療として使用した DA の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

表 2.7.3.6-72　前治療として使用した DA の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=51)	Screening -3	5	11.64	0.75	10.4	12.00	12.3						
	Screening -2	51	11.02	0.66	9.8	11.00	12.2						
	Screening -1	51	10.99	0.60	9.8	11.00	12.5						
	Week 0	51	10.87	0.68	9.3	10.90	12.0						
	Baseline	51	10.97	0.59	9.8	10.93	11.9						
	Week 2	50	10.78	0.83	8.6	10.80	12.2	50	-0.18	0.62	-1.8	-0.15	1.3
	Week 4	50	10.60	1.06	8.3	10.70	12.5	50	-0.37	0.97	-3.5	-0.18	1.3
	Week 6	49	10.54	1.25	8.1	10.90	12.6	49	-0.42	1.23	-3.2	-0.10	1.8
	Week 8	49	10.52	1.30	7.6	10.70	12.5	49	-0.44	1.31	-3.3	-0.07	1.7
	Week 10	48	10.62	1.39	7.6	10.80	13.1	48	-0.35	1.41	-3.4	-0.10	2.1
	Week 12	48	10.65	1.39	7.4	10.80	12.8	48	-0.32	1.45	-3.8	-0.02	2.5
	Week 14	44	10.92	1.32	8.1	11.15	13.5	44	-0.06	1.36	-3.3	0.10	2.6
	Week 16	44	11.03	1.07	8.3	11.10	12.7	44	0.06	1.21	-3.5	0.12	2.5
	Week 18	43	11.18	1.00	8.7	11.20	13.3	43	0.19	1.15	-3.1	0.27	2.1
	Week 20	43	11.21	0.95	8.4	11.20	13.4	43	0.21	1.09	-3.4	0.37	2.1
	Week 22	43	11.25	0.72	9.0	11.20	12.7	43	0.25	0.91	-2.8	0.30	2.0
	Week 24	41	11.29	0.75	9.4	11.30	13.0	41	0.26	0.95	-2.4	0.23	2.5
	Week 26	43	11.30	0.80	9.6	11.30	12.6	43	0.31	1.05	-2.2	0.30	2.2
	Week 28	42	11.33	0.76	9.2	11.50	12.5	42	0.33	0.99	-2.0	0.40	2.2
	Week 30	42	11.30	0.80	8.9	11.40	12.7	42	0.30	0.96	-1.9	0.37	2.4
	Week 32	42	11.31	0.88	9.1	11.50	12.9	42	0.30	1.05	-1.8	0.53	2.3
	Week 33	41	11.32	0.87	9.2	11.40	12.7	41	0.31	1.07	-1.6	0.53	2.4
	Week 34	41	11.25	0.88	8.9	11.40	12.6	41	0.24	1.06	-1.9	0.20	2.2
	Week 35	41	11.18	0.88	8.9	11.20	12.5	41	0.17	1.07	-1.9	0.43	2.1
	Week 36	40	11.13	0.87	8.8	11.30	12.5	40	0.12	1.08	-1.7	0.28	2.0
	Week 38	41	11.04	0.88	8.4	11.10	12.7	41	0.03	1.10	-1.9	0.05	2.2
	Week 40	40	11.01	0.84	8.6	11.20	12.2	40	-0.02	1.03	-2.2	0.22	1.8
	Week 42	40	11.00	0.79	9.3	11.00	12.5	40	-0.02	0.96	-2.6	0.25	1.5
	Week 44	39	11.08	0.74	9.9	11.00	12.9	39	0.08	0.88	-1.4	-0.03	2.0
	Week 46	39	11.04	0.80	9.3	11.00	12.7	39	0.04	0.88	-2.0	0.03	1.8
	Week 48	39	10.99	0.85	9.3	11.00	12.3	39	-0.01	1.01	-2.4	0.13	1.8
	Week 50	39	11.06	0.92	9.6	11.00	13.3	39	0.06	1.08	-2.2	0.00	2.2
	Week 52	39	11.03	0.90	9.0	11.00	14.1	39	0.02	1.13	-2.8	0.15	3.3
	Evaluation period	51	10.95	1.10	7.4	11.18	12.2	51	-0.02	1.25	-3.8	0.25	2.0
	End of Follow-Up	50	10.76	0.86	9.1	10.80	13.3	50	-0.21	1.19	-2.4	-0.28	3.4

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=18)	Screening -4	1	12.40	.	12.4	12.40	12.4						
	Screening -3	2	11.75	0.07	11.7	11.75	11.8						
	Screening -2	18	11.37	0.58	10.1	11.40	12.3						
	Screening -1	18	11.15	0.56	9.7	11.25	12.1						
	Week 0	18	11.20	0.56	10.0	11.25	12.4						
	Baseline	18	11.26	0.53	10.0	11.33	12.0						
	Week 2	18	11.17	0.61	10.0	11.25	12.5	18	-0.08	0.40	-0.8	-0.12	0.5
	Week 4	18	11.16	0.71	9.2	11.25	12.3	18	-0.10	0.42	-0.9	-0.03	0.7
	Week 6	18	11.17	0.61	9.6	11.15	12.2	18	-0.09	0.55	-1.2	0.05	0.9
	Week 8	17	10.95	0.83	8.9	11.10	11.9	17	-0.27	0.81	-2.6	-0.20	0.9
	Week 10	17	10.72	0.93	8.0	10.90	12.2	17	-0.50	1.06	-3.5	-0.40	1.0
	Week 12	17	10.72	0.87	8.6	10.90	11.9	17	-0.50	0.98	-2.9	-0.27	0.7
	Week 14	17	10.80	0.90	8.3	10.80	12.0	17	-0.42	0.96	-3.2	-0.23	0.6
	Week 16	17	10.85	0.79	9.2	11.10	11.9	17	-0.37	0.98	-2.7	-0.13	0.9
	Week 18	16	11.01	0.64	9.6	11.30	12.0	16	-0.16	0.80	-1.9	0.03	0.9
	Week 20	17	10.89	0.58	9.6	11.00	11.9	17	-0.33	0.90	-2.2	-0.13	1.0
	Week 22	17	11.05	0.47	10.2	11.00	11.9	17	-0.17	0.63	-1.2	-0.30	1.1
	Week 24	17	10.89	1.28	6.7	11.20	12.3	17	-0.33	1.41	-4.6	-0.13	1.9
	Week 26	17	10.83	1.07	7.7	11.00	13.0	17	-0.39	1.16	-3.6	0.03	1.5
	Week 28	17	10.94	0.99	8.8	10.90	13.6	17	-0.28	1.06	-2.5	-0.27	2.1
	Week 30	17	10.77	0.95	9.0	10.60	13.2	17	-0.45	1.09	-2.0	-0.43	1.7
	Week 32	17	10.79	0.71	9.1	10.80	12.2	17	-0.43	0.88	-1.8	-0.28	1.1
	Week 33	17	10.85	0.77	9.2	11.00	12.2	17	-0.37	0.99	-2.4	-0.18	1.0
	Week 34	17	10.68	0.70	9.2	10.80	11.6	17	-0.54	0.92	-2.8	-0.23	1.1
	Week 35	17	10.84	0.85	9.1	10.80	12.8	17	-0.38	1.01	-2.9	-0.30	1.5
	Week 36	17	10.74	0.84	9.5	10.70	12.6	17	-0.48	0.97	-2.5	-0.53	1.3
	Week 38	17	10.88	0.79	9.7	10.90	12.9	17	-0.34	0.85	-1.8	-0.20	1.6
	Week 40	17	10.88	0.90	9.1	11.00	12.3	17	-0.34	0.88	-1.9	-0.17	1.0
	Week 42	17	10.64	0.95	8.8	10.60	12.1	17	-0.58	0.90	-2.2	-0.60	0.8
	Week 44	17	10.71	0.96	9.2	10.50	12.4	17	-0.51	0.95	-2.0	-0.73	1.1
	Week 46	17	10.67	1.07	9.0	10.20	13.1	17	-0.55	1.11	-2.3	-0.70	1.6
	Week 48	17	10.56	1.01	9.0	10.40	12.3	17	-0.66	1.08	-2.5	-0.77	0.9
	Week 50	16	10.90	0.73	9.3	11.00	12.2	16	-0.28	0.87	-2.1	0.03	0.7
	Week 52	15	10.87	0.73	9.7	10.90	11.9	15	-0.32	0.84	-2.2	-0.30	0.8
	Evaluation period	18	10.84	0.76	9.4	10.96	12.0	18	-0.41	0.90	-2.6	-0.29	0.9
	End of Follow-Up	17	10.89	0.76	9.2	10.90	12.4	17	-0.33	0.91	-1.7	-0.60	1.1

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period


Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=35)	Screening -6	1	12.40	.	12.4	12.40	12.4						
	Screening -5	1	12.20	.	12.2	12.20	12.2						
	Screening -4	4	11.00	1.28	9.1	11.55	11.8						
	Screening -3	8	10.75	1.13	9.5	10.50	12.5						
	Screening -2	35	10.65	0.74	9.3	10.60	12.0						
	Screening -1	35	10.84	0.68	9.6	10.80	12.1						
	Week 0	35	10.75	0.76	9.4	10.70	12.1						
	Baseline	35	10.74	0.70	9.6	10.80	11.9						
	Week 2	34	10.61	0.84	8.8	10.80	12.2	34	-0.16	0.57	-1.3	-0.20	1.2
	Week 4	33	10.37	1.16	8.0	10.60	12.6	33	-0.41	1.08	-2.3	-0.53	2.7
	Week 6	32	10.02	1.36	7.1	10.25	13.4	32	-0.80	1.33	-3.8	-0.87	3.5
	Week 8	29	10.13	1.30	8.0	10.00	12.5	29	-0.68	1.31	-3.0	-0.87	2.6
	Week 10	28	10.22	1.12	8.2	10.45	12.2	28	-0.58	1.13	-2.4	-0.63	1.5
	Week 12	27	10.26	1.26	8.0	10.30	12.5	27	-0.58	1.25	-2.8	-0.50	1.5
	Week 14	27	10.40	1.28	8.3	10.30	12.3	27	-0.44	1.36	-2.4	-0.23	2.7
	Week 16	26	10.66	1.39	8.2	10.85	12.9	26	-0.18	1.49	-2.6	-0.38	3.3
	Week 18	26	10.80	1.09	9.0	10.75	12.9	26	-0.04	1.28	-2.0	-0.22	2.7
	Week 20	26	11.07	1.12	9.0	11.15	13.2	26	0.23	1.24	-1.4	0.17	2.9
	Week 22	26	11.22	0.80	9.4	11.20	12.7	26	0.38	0.93	-0.8	0.11	3.1
	Week 24	26	11.21	0.99	9.3	11.10	13.4	26	0.37	1.06	-1.0	0.47	3.8
	Week 26	26	11.11	1.04	9.1	11.10	13.7	26	0.27	1.21	-2.1	0.35	4.1
	Week 28	26	11.14	1.00	9.3	11.05	13.1	26	0.30	1.15	-1.8	0.17	2.9
	Week 30	25	10.96	0.86	9.5	10.80	13.4	25	0.11	0.98	-1.4	-0.17	2.5
	Week 32	25	10.82	0.72	9.6	10.80	12.2	25	-0.03	0.84	-1.6	-0.07	1.8
	Week 33	25	10.70	0.75	9.4	10.60	12.2	25	-0.15	0.80	-1.8	-0.47	1.6
	Week 34	25	10.68	0.74	9.4	10.80	12.4	25	-0.17	0.83	-1.5	-0.40	2.4
	Week 35	25	10.55	0.87	8.8	10.70	11.8	25	-0.30	0.96	-1.7	-0.47	2.2
	Week 36	25	10.54	0.78	9.2	10.80	11.7	25	-0.31	0.91	-1.9	-0.48	2.1
	Week 38	25	10.59	0.79	9.3	10.50	12.1	25	-0.26	0.96	-1.9	-0.60	2.3
	Week 40	25	10.63	0.76	9.3	10.60	12.3	25	-0.22	1.01	-1.9	-0.28	2.7
	Week 42	22	10.69	0.84	9.7	10.45	12.5	22	-0.27	0.96	-2.0	-0.43	1.8
	Week 44	22	10.92	1.06	9.5	10.60	14.1	22	-0.04	1.17	-1.9	-0.20	2.3
	Week 46	22	10.95	0.90	9.9	10.65	13.6	22	-0.01	1.05	-1.8	-0.10	1.8
	Week 48	22	10.85	0.81	9.5	10.85	12.2	22	-0.11	0.90	-1.9	-0.05	1.1
	Week 50	22	11.09	1.22	9.4	10.85	15.2	22	0.13	1.18	-2.0	0.20	3.4
	Week 52	22	11.16	1.11	8.8	11.25	13.4	22	0.20	0.92	-2.0	0.45	1.5
	Evaluation period	35	10.21	1.20	7.1	10.30	11.7	35	-0.53	1.24	-3.8	-0.55	2.1
	End of Follow-Up	34	10.49	1.18	8.0	10.35	13.4	34	-0.27	1.15	-2.3	-0.17	2.0


Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=17)	Screening -3	3	10.80	0.70	10.1	10.80	11.5						
	Screening -2	17	10.78	0.85	9.5	10.80	12.5						
	Screening -1	17	10.91	0.65	10.0	10.80	12.1						
	Week 0	17	10.79	0.69	9.2	10.80	12.1						
	Baseline	17	10.80	0.63	9.6	10.87	11.9						
	Week 2	17	10.79	0.64	9.8	10.70	12.3	17	-0.01	0.54	-1.0	0.07	0.9
	Week 4	16	10.73	0.66	9.2	10.80	12.1	16	-0.06	0.72	-2.0	0.05	0.9
	Week 6	16	10.73	0.82	9.6	10.50	12.2	16	-0.05	0.97	-1.6	-0.07	1.5
	Week 8	16	10.97	0.83	9.8	10.85	12.7	16	0.19	1.01	-1.2	0.03	2.0
	Week 10	16	10.74	0.88	9.2	10.90	12.0	16	-0.04	1.28	-1.9	-0.02	1.7
	Week 12	16	10.89	0.90	9.3	10.90	12.2	16	0.11	1.30	-2.0	0.43	2.0
	Week 14	14	11.13	0.73	9.4	11.30	12.1	14	0.44	1.02	-2.0	0.73	1.8
	Week 16	14	11.09	0.79	9.7	11.30	12.2	14	0.40	1.12	-1.7	0.37	2.0
	Week 18	14	11.04	0.95	9.4	11.10	12.6	14	0.35	1.24	-1.8	0.53	1.8
	Week 20	14	11.02	0.92	9.3	11.20	12.2	14	0.33	1.19	-1.6	0.73	2.3
	Week 22	14	10.74	0.87	9.6	10.75	11.9	14	0.05	0.96	-1.6	0.37	1.5
	Week 24	14	10.63	0.79	9.3	10.80	12.0	14	-0.06	0.75	-1.2	-0.17	1.3
	Week 26	14	10.81	0.67	9.6	10.85	11.7	14	0.12	0.72	-0.9	0.10	1.2
	Week 28	14	11.04	0.74	9.9	10.95	12.3	14	0.35	0.70	-0.7	0.37	1.6
	Week 30	14	11.03	0.72	10.2	10.85	12.7	14	0.34	0.85	-1.0	0.25	2.0
	Week 32	14	11.10	0.66	10.0	11.10	12.4	14	0.41	0.78	-0.6	0.35	1.7
	Week 33	14	11.07	0.88	9.6	11.00	12.6	14	0.38	0.83	-0.8	0.18	1.9
	Week 34	14	11.21	0.76	10.3	11.25	12.6	14	0.53	0.98	-1.0	0.32	2.2
	Week 35	14	11.19	0.68	10.1	11.30	12.2	14	0.50	0.89	-0.9	0.63	2.3
	Week 36	14	11.15	0.68	10.0	11.05	12.2	14	0.46	0.98	-1.2	0.31	2.3
	Week 38	14	10.94	0.85	9.6	10.95	13.1	14	0.25	1.18	-1.1	-0.12	3.5
	Week 40	14	10.47	0.74	9.1	10.60	11.8	14	-0.22	1.00	-1.6	-0.39	2.0
	Week 42	14	10.37	0.92	8.7	10.35	12.2	14	-0.32	1.22	-2.5	-0.43	2.1
	Week 44	14	10.63	0.98	8.5	10.65	12.4	14	-0.06	1.35	-2.7	0.18	2.8
	Week 46	14	10.63	0.85	8.4	10.90	11.6	14	-0.06	1.20	-2.8	0.38	2.0
	Week 48	14	10.83	0.89	8.8	10.90	12.2	14	0.14	1.22	-2.4	0.40	2.6
	Week 50	14	11.00	0.68	9.9	11.15	11.9	14	0.31	1.01	-1.3	0.57	2.2
	Week 52	14	10.91	0.76	9.6	10.95	12.3	14	0.22	0.93	-1.6	0.20	1.6
	Evaluation period	17	10.99	0.78	9.3	11.13	12.2	17	0.19	1.06	-1.7	0.13	2.0
	End of Follow-Up	16	10.46	1.13	8.4	10.45	12.5	16	-0.28	1.14	-2.6	-0.45	1.5

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

図 2.7.3.6-32 前治療として使用した PEGOL の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

表 2.7.3.6-73 前治療として使用した PEGOL の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=10)	Screening -3	1	11.40	.	11.4	11.40	11.4						
	Screening -2	10	11.21	0.59	10.2	11.40	11.9						
	Screening -1	10	10.83	0.70	9.6	11.05	11.9						
	Week 0	10	10.84	0.82	9.0	11.00	11.9						
	Baseline	10	10.96	0.67	9.6	11.15	11.9						
	Week 2	10	11.02	1.06	8.6	11.05	12.6	10	0.06	0.59	-1.0	0.07	1.1
	Week 4	10	11.09	1.17	8.2	11.20	12.5	10	0.13	0.76	-1.4	0.18	1.0
	Week 6	10	11.25	1.28	8.1	11.45	12.8	10	0.29	0.84	-1.5	0.45	1.3
	Week 8	10	11.19	1.28	8.5	11.60	12.8	10	0.23	0.94	-1.1	0.50	1.5
	Week 10	10	11.24	1.13	9.0	11.70	12.3	10	0.28	0.88	-1.4	0.53	1.3
	Week 12	10	11.33	1.35	8.6	11.80	13.5	10	0.37	1.08	-1.1	0.43	2.3
	Week 14	10	11.28	1.40	8.7	11.75	12.9	10	0.32	1.30	-2.5	0.55	1.8
	Week 16	10	11.51	1.14	9.5	12.10	12.7	10	0.55	0.99	-1.1	0.48	1.9
	Week 18	10	11.58	0.96	9.4	11.90	12.5	10	0.62	0.85	-0.4	0.93	1.9
	Week 20	10	11.50	0.99	10.0	11.60	13.2	10	0.54	1.07	-1.1	0.65	2.2
	Week 22	10	11.44	0.68	10.3	11.50	12.7	10	0.48	0.71	-0.5	0.55	1.7
	Week 24	10	11.76	0.87	10.4	11.70	13.3	10	0.80	1.07	-0.9	0.78	2.3
	Week 26	10	11.53	0.96	9.9	11.40	13.1	10	0.57	1.17	-1.3	0.73	2.1
	Week 28	10	11.49	1.15	9.9	11.70	13.4	10	0.53	1.40	-2.0	0.88	2.4
	Week 30	10	11.43	1.13	10.0	11.50	13.2	10	0.47	1.39	-1.9	0.68	2.2
	Week 32	10	11.57	1.06	9.8	11.90	12.7	10	0.61	1.36	-1.7	0.88	2.3
	Week 33	10	11.51	1.14	9.8	11.70	13.1	10	0.55	1.35	-1.6	0.88	2.1
	Week 34	10	11.36	1.15	9.8	11.45	13.2	10	0.40	1.33	-2.1	0.68	2.2
	Week 35	10	11.45	1.06	10.0	11.50	13.5	10	0.49	1.41	-1.9	0.48	2.5
	Week 36	10	11.47	0.95	9.7	11.75	13.0	10	0.51	1.33	-2.2	0.67	2.0
	Week 38	10	11.31	0.90	9.9	11.20	12.7	10	0.35	1.26	-2.0	0.58	2.1
	Week 40	10	11.26	0.84	10.3	11.10	12.9	10	0.30	1.21	-1.6	0.33	1.9
	Week 42	10	11.34	0.93	10.1	11.40	12.6	10	0.38	1.22	-1.8	0.52	1.9
	Week 44	10	11.29	0.83	10.1	11.00	12.7	10	0.33	1.17	-1.1	0.03	2.4
	Week 46	10	11.44	0.96	9.9	11.70	12.9	10	0.48	1.25	-1.3	0.57	2.2
	Week 48	10	11.64	1.20	10.2	11.40	13.7	10	0.68	1.56	-1.0	0.58	4.1
	Week 50	10	11.36	0.87	10.3	11.35	12.7	10	0.40	1.26	-1.5	0.47	2.7
	Week 52	10	11.39	0.77	10.2	11.15	12.8	10	0.43	0.89	-1.0	0.58	1.8
	Evaluation period	10	11.45	1.04	10.0	11.68	13.2	10	0.49	1.33	-2.0	0.76	2.2
	End of Follow-Up	10	11.00	1.11	9.1	10.85	12.5	10	0.04	1.17	-2.1	0.37	1.5

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Low (<= 15.625 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=4)	Screening -3	1	11.20	.	11.2	11.20	11.2						
	Screening -2	4	11.18	0.75	10.3	11.15	12.1						
	Screening -1	4	11.25	0.52	10.5	11.45	11.6						
	Week 0	4	11.20	1.07	9.7	11.50	12.1						
	Baseline	4	11.20	0.75	10.2	11.36	11.9						
	Week 2	3	11.37	1.12	10.1	11.80	12.2	3	0.18	0.48	-0.1	-0.07	0.7
	Week 4	3	11.23	1.24	9.8	11.90	12.0	3	0.04	0.40	-0.4	0.07	0.4
	Week 6	3	11.67	1.29	10.2	12.20	12.6	3	0.48	0.58	0.0	0.27	1.1
	Week 8	3	11.67	0.61	11.0	11.80	12.2	3	0.48	0.53	-0.1	0.73	0.8
	Week 10	3	11.53	0.55	10.9	11.80	11.9	3	0.34	0.38	0.0	0.33	0.7
	Week 12	3	11.50	0.10	11.4	11.50	11.6	3	0.31	1.01	-0.5	0.03	1.4
	Week 14	3	11.37	0.46	11.1	11.10	11.9	3	0.18	0.91	-0.8	0.43	0.9
	Week 16	3	10.97	0.47	10.6	10.80	11.5	3	-0.22	1.01	-1.3	0.03	0.6
	Week 18	3	11.30	0.85	10.5	11.20	12.2	3	0.11	1.76	-1.4	-0.27	2.0
	Week 20	3	10.80	0.52	10.5	10.50	11.4	3	-0.39	0.93	-1.4	-0.07	0.3
	Week 22	3	10.57	0.25	10.3	10.60	10.8	3	-0.62	1.15	-1.6	-0.87	0.6
	Week 24	3	10.40	0.35	10.0	10.60	10.6	3	-0.79	1.19	-1.9	-0.87	0.4
	Week 26	3	10.57	0.06	10.5	10.60	10.6	3	-0.62	0.86	-1.3	-0.87	0.3
	Week 28	3	10.73	0.21	10.5	10.80	10.9	3	-0.46	0.74	-1.1	-0.57	0.3
	Week 30	3	10.63	0.38	10.2	10.80	10.9	3	-0.56	0.58	-1.1	-0.57	0.0
	Week 32	3	10.63	0.64	9.9	10.90	11.1	3	-0.56	0.42	-1.0	-0.37	-0.3
	Week 33	3	10.87	0.12	10.8	10.80	11.0	3	-0.32	0.84	-0.9	-0.67	0.6
	Week 34	3	10.60	0.50	10.1	10.60	11.1	3	-0.59	0.45	-0.9	-0.83	-0.1
	Week 35	3	10.77	0.21	10.6	10.70	11.0	3	-0.42	0.75	-0.9	-0.77	0.4
	Week 36	3	10.70	0.56	10.1	10.80	11.2	3	-0.49	1.02	-1.4	-0.73	0.6
	Week 38	3	10.43	0.75	10.0	10.00	11.3	3	-0.76	0.66	-1.5	-0.63	-0.2
	Week 40	3	10.60	0.56	10.1	10.50	11.2	3	-0.59	0.86	-1.4	-0.73	0.3
	Week 42	3	10.93	0.65	10.3	10.90	11.6	3	-0.26	0.95	-1.2	-0.33	0.7
	Week 44	3	11.00	0.56	10.4	11.10	11.5	3	-0.19	1.02	-1.1	-0.43	0.9
	Week 46	3	10.97	0.42	10.5	11.10	11.3	3	-0.22	1.01	-1.0	-0.63	0.9
	Week 48	3	11.20	0.36	10.8	11.30	11.5	3	0.01	0.98	-0.7	-0.43	1.1
	Week 50	3	11.57	0.42	11.1	11.70	11.9	3	0.38	1.01	-0.4	-0.03	1.5
	Week 52	3	11.33	0.21	11.1	11.40	11.5	3	0.14	1.03	-0.5	-0.37	1.3
	Evaluation period	4	10.30	0.90	9.0	10.56	11.1	4	-0.90	1.09	-2.3	-0.89	0.4
	End of Follow-Up	4	11.15	0.17	10.9	11.20	11.3	4	-0.05	0.84	-0.7	-0.31	1.1

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period


Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=9)	Screening -3	1	8.90	.	8.9	8.90	8.9						
	Screening -2	9	10.29	0.87	9.3	10.20	11.9						
	Screening -1	9	10.48	0.58	9.9	10.40	11.8						
	Week 0	9	10.59	0.87	9.2	10.80	12.1						
	Baseline	9	10.43	0.76	9.5	10.20	11.9						
	Week 2	9	10.71	0.96	9.6	10.70	12.7	9	0.28	0.43	-0.5	0.30	0.8
	Week 4	9	10.61	0.94	9.1	10.60	11.6	9	0.18	0.69	-0.5	0.03	1.4
	Week 6	9	10.97	1.11	8.8	11.40	12.7	9	0.54	0.74	-0.8	0.77	1.5
	Week 8	9	11.06	1.23	8.9	11.20	12.8	9	0.63	0.83	-0.7	0.60	2.3
	Week 10	9	11.04	1.19	8.6	11.70	12.2	9	0.61	0.94	-1.0	0.70	2.1
	Week 12	9	11.29	1.82	7.9	11.80	13.4	9	0.86	1.55	-1.7	0.80	3.3
	Week 14	9	11.29	1.55	8.7	12.10	12.7	9	0.86	1.24	-0.8	1.10	2.6
	Week 16	9	11.43	1.91	8.2	11.80	14.1	9	1.00	1.47	-1.3	0.70	2.9
	Week 18	9	10.83	1.51	8.6	11.60	12.6	9	0.40	1.31	-1.1	0.00	2.5
	Week 20	9	10.77	1.61	7.5	11.60	12.5	9	0.34	1.18	-2.0	0.57	1.7
	Week 22	9	10.24	1.48	7.0	10.80	11.7	9	-0.19	1.22	-2.5	-0.30	1.4
	Week 24	9	10.36	1.41	7.7	10.20	12.2	9	-0.08	1.13	-1.8	-0.30	2.1
	Week 26	9	10.76	0.97	9.7	10.40	12.3	9	0.33	0.81	-0.9	0.20	1.9
	Week 28	9	10.46	0.84	8.7	10.40	11.4	9	0.03	1.12	-1.9	0.20	1.7
	Week 30	9	10.82	1.30	8.7	10.60	12.8	9	0.39	1.41	-1.9	0.80	2.3
	Week 32	9	10.90	0.90	9.3	11.00	11.9	9	0.47	1.27	-1.4	0.77	2.4
	Week 33	9	10.80	0.80	9.4	10.90	11.9	9	0.37	1.30	-1.2	0.70	2.3
	Week 34	9	11.16	0.85	9.8	11.10	12.2	9	0.73	1.24	-1.3	0.97	2.4
	Week 35	9	11.26	0.85	9.9	11.20	12.7	9	0.83	1.28	-1.2	0.77	3.2
	Week 36	9	11.20	0.74	9.7	11.20	12.4	9	0.77	1.21	-1.4	0.87	2.9
	Week 38	9	11.12	0.71	10.0	11.00	12.3	9	0.69	0.95	-1.1	0.57	2.0
	Week 40	9	11.04	0.99	9.5	11.20	12.7	9	0.61	1.13	-1.6	0.57	2.1
	Week 42	9	11.28	1.11	10.1	11.00	13.4	9	0.85	1.04	-0.8	0.63	2.8
	Week 44	9	11.17	0.60	10.4	11.00	12.4	9	0.74	0.88	-0.9	0.70	2.1
	Week 46	9	11.02	0.63	10.3	11.10	12.0	9	0.59	1.09	-1.6	0.70	2.4
	Week 48	9	11.22	0.53	10.5	11.00	12.1	9	0.79	0.82	-0.2	0.80	2.5
	Week 50	9	10.88	0.90	9.5	10.70	12.6	9	0.45	1.04	-0.5	0.03	3.0
	Week 52	9	10.64	1.21	8.0	10.90	12.3	9	0.21	1.26	-1.5	0.17	2.7
	Evaluation period	9	11.10	0.77	9.8	11.03	12.2	9	0.67	1.23	-1.3	0.87	2.7
	End of Follow-Up	9	10.61	1.24	8.7	10.70	12.4	9	0.18	1.52	-1.5	0.00	2.8


Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: High (> 15.625 ug/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=5)	Screening -3	1	10.30	.	10.3	10.30	10.3						
	Screening -2	5	10.22	0.33	9.7	10.30	10.6						
	Screening -1	5	10.46	0.34	10.2	10.30	11.0						
	Week 0	5	10.34	0.89	9.5	10.00	11.8						
	Baseline	5	10.33	0.45	9.8	10.27	11.0						
	Week 2	5	10.42	1.05	9.0	10.60	11.7	5	0.09	0.72	-0.8	0.18	0.9
	Week 4	5	10.52	1.09	8.9	10.40	11.8	5	0.19	0.77	-0.9	0.03	1.1
	Week 6	5	10.68	1.00	9.3	10.40	11.8	5	0.35	0.73	-0.5	0.13	1.4
	Week 8	5	10.40	0.92	9.4	10.30	11.9	5	0.07	0.53	-0.4	0.03	0.9
	Week 10	5	10.20	1.11	9.2	10.00	11.9	5	-0.13	0.80	-1.1	-0.27	0.9
	Week 12	5	10.44	0.76	9.2	10.50	11.1	5	0.11	0.53	-0.6	0.07	0.9
	Week 14	5	10.14	0.54	9.4	10.20	10.9	5	-0.19	0.60	-0.8	-0.40	0.8
	Week 16	5	10.36	0.55	9.9	10.20	11.2	5	0.03	0.80	-1.1	0.10	1.1
	Week 18	5	10.22	1.05	8.6	10.20	11.3	5	-0.11	1.39	-2.4	0.40	1.2
	Week 20	5	10.00	1.10	8.3	10.10	11.4	5	-0.33	1.48	-2.7	-0.17	1.3
	Week 22	5	10.14	0.86	8.7	10.50	10.8	5	-0.19	1.26	-2.3	0.28	0.7
	Week 24	5	9.96	0.73	9.1	10.20	10.8	5	-0.37	1.11	-1.9	0.13	0.7
	Week 26	5	10.36	0.86	9.4	10.60	11.2	5	0.03	1.22	-1.6	0.80	1.0
	Week 28	5	10.74	0.80	9.4	11.10	11.4	5	0.41	1.06	-1.0	1.07	1.3
	Week 30	5	10.42	1.17	8.5	10.50	11.5	5	0.09	1.39	-1.9	0.37	1.4
	Week 32	5	10.90	1.31	9.0	11.20	12.2	5	0.57	1.47	-1.4	0.17	2.1
	Week 33	5	11.26	1.33	9.6	11.60	12.8	5	0.93	1.45	-0.8	0.57	2.5
	Week 34	5	11.06	1.49	9.5	10.80	12.7	5	0.73	1.72	-0.9	-0.23	2.9
	Week 35	5	10.84	1.14	9.5	10.70	12.1	5	0.51	1.38	-0.9	-0.13	2.3
	Week 36	5	10.92	0.73	10.2	10.80	11.9	5	0.59	1.00	-0.2	0.07	2.1
	Week 38	5	11.20	0.87	10.2	11.10	12.6	5	0.87	1.13	0.1	0.58	2.8
	Week 40	5	11.26	0.92	10.2	11.10	12.2	5	0.93	1.17	-0.4	0.83	2.4
	Week 42	5	10.96	0.92	9.7	10.90	11.9	5	0.63	1.14	-0.5	0.63	2.1
	Week 44	5	10.50	0.93	9.6	10.60	11.9	5	0.17	0.82	-0.5	-0.10	1.5
	Week 46	5	10.54	0.99	9.6	10.50	12.1	5	0.21	0.91	-0.5	0.00	1.7
	Week 48	5	10.62	1.02	9.6	10.50	12.3	5	0.29	1.03	-0.9	0.33	1.9
	Week 50	5	10.78	0.73	9.7	10.90	11.7	5	0.45	0.70	-0.4	0.73	1.3
	Week 52	5	11.00	0.78	9.7	11.20	11.8	5	0.67	0.74	-0.1	0.88	1.7
	Evaluation period	5	11.02	1.15	9.7	10.98	12.2	5	0.69	1.36	-0.7	-0.06	2.4
	End of Follow-Up	5	10.32	1.44	8.8	10.00	12.7	5	-0.01	1.72	-2.2	-0.07	2.6

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

図 2.7.3.6-33 前治療として使用した rHuEPO の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

表 2.7.3.6-74 前治療として使用した rHuEPO の用量別（中央値以下又は中央値超別）の各来院時の平均 Hb 値（g/dL、平均値±SD）の推移（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=25)	Screening -3	1	11.50	.	11.5	11.50	11.5						
	Screening -2	25	10.50	0.60	9.2	10.40	12.1						
	Screening -1	25	10.52	0.60	9.4	10.50	11.9						
	Week 0	25	10.39	0.62	9.0	10.30	11.4						
	Baseline	25	10.47	0.54	9.5	10.43	11.6						
	Week 2	25	10.56	0.88	9.1	10.60	12.4	25	0.09	0.68	-1.1	0.00	1.7
	Week 4	24	10.75	1.38	8.2	10.80	13.4	24	0.27	1.13	-1.8	0.46	2.5
	Week 6	24	10.82	1.62	7.4	11.00	13.7	24	0.35	1.34	-2.7	0.63	2.8
	Week 8	21	11.37	1.38	9.0	11.20	14.2	21	0.83	1.14	-1.0	0.70	3.3
	Week 10	22	11.37	1.53	7.1	11.55	13.7	22	0.85	1.27	-3.1	0.98	2.8
	Week 12	21	11.49	1.18	9.1	11.30	14.0	21	0.95	0.94	-0.9	0.80	3.1
	Week 14	21	11.50	1.06	9.8	11.40	13.9	21	0.96	0.83	-0.1	0.67	3.2
	Week 16	21	11.33	1.12	8.0	11.40	13.4	21	0.79	1.00	-2.0	0.83	2.7
	Week 18	21	11.40	0.87	9.5	11.40	12.8	21	0.85	0.78	-0.6	0.87	2.1
	Week 20	21	11.20	0.71	9.8	11.30	12.7	21	0.65	0.69	-0.7	0.73	1.8
	Week 22	21	11.16	0.82	9.6	11.00	12.8	21	0.62	0.92	-1.5	0.77	2.1
	Week 24	21	11.07	0.82	9.7	11.00	12.8	21	0.53	0.90	-1.3	0.53	2.1
	Week 26	20	11.14	0.79	9.9	11.20	12.4	20	0.58	0.91	-1.1	0.52	1.9
	Week 28	20	11.13	0.57	10.0	11.20	12.0	20	0.58	0.79	-1.1	0.73	1.8
	Week 30	19	11.01	0.76	9.4	11.10	12.4	19	0.43	0.99	-2.1	0.67	1.7
	Week 32	20	11.00	0.75	9.7	11.05	12.1	20	0.45	0.98	-1.8	0.65	1.9
	Week 33	19	11.07	0.90	9.2	11.00	12.9	19	0.50	1.06	-2.3	0.53	2.2
	Week 34	19	11.02	0.92	9.5	11.00	13.1	19	0.46	1.11	-2.0	0.40	2.4
	Week 35	19	11.07	1.00	9.5	11.20	12.7	19	0.51	1.11	-2.0	0.63	2.1
	Week 36	19	11.04	0.90	9.1	11.30	12.4	19	0.47	1.14	-2.4	0.55	2.1
	Week 38	19	11.04	0.80	9.5	11.00	12.2	19	0.47	1.02	-1.9	0.45	2.7
	Week 40	19	11.04	0.77	9.5	11.00	12.5	19	0.47	1.07	-2.0	0.60	3.0
	Week 42	19	11.06	0.72	9.7	10.90	12.7	19	0.49	1.04	-1.8	0.50	3.2
	Week 44	19	10.97	0.85	9.6	10.80	12.7	19	0.40	1.14	-1.7	0.20	3.2
	Week 46	19	11.14	0.88	9.9	11.10	12.6	19	0.58	1.17	-1.5	0.37	2.9
	Week 48	19	11.13	0.80	10.2	11.10	13.0	19	0.57	1.09	-1.3	0.23	2.8
	Week 50	19	11.22	0.86	10.1	11.00	13.4	19	0.65	1.14	-1.1	0.57	3.2
	Week 52	19	11.11	0.88	10.1	11.10	13.0	19	0.55	1.09	-1.0	0.27	3.0
	Evaluation period	25	10.45	1.54	7.1	11.00	12.8	25	-0.03	1.50	-3.1	0.30	2.1
	End of Follow-Up	25	10.87	1.06	8.4	11.00	12.6	25	0.40	1.08	-2.1	0.40	2.4

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Low (<= 3000.000 IU/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=20)	Screening -6	1	9.20	.	9.2	9.20	9.2						
	Screening -5	1	9.00	.	9.0	9.00	9.0						
	Screening -4	2	10.75	1.77	9.5	10.75	12.0						
	Screening -3	4	11.03	1.07	9.6	11.20	12.1						
	Screening -2	20	10.87	0.61	10.0	10.80	11.9						
	Screening -1	20	10.69	0.77	9.6	10.65	12.4						
	Week 0	20	10.59	0.64	9.7	10.40	12.1						
	Baseline	20	10.70	0.66	9.6	10.55	11.9						
	Week 2	20	10.72	0.51	10.0	10.60	11.6	20	0.01	0.43	-0.6	-0.08	0.9
	Week 4	19	10.76	0.44	10.0	10.70	11.8	19	0.11	0.67	-1.2	0.13	1.4
	Week 6	19	10.95	0.62	9.9	10.80	12.3	19	0.30	0.86	-1.0	0.23	2.3
	Week 8	19	11.14	0.49	10.4	11.00	12.2	19	0.49	0.85	-1.3	0.53	2.2
	Week 10	19	11.18	0.48	10.2	11.20	12.1	19	0.54	0.87	-1.2	0.63	2.1
	Week 12	19	11.20	0.70	10.2	11.20	12.8	19	0.55	1.04	-1.6	0.63	2.8
	Week 14	19	11.16	0.84	9.1	11.30	12.1	19	0.51	1.17	-1.4	0.70	2.3
	Week 16	19	11.17	0.80	9.7	11.30	12.4	19	0.52	1.14	-1.8	0.43	2.6
	Week 18	19	11.01	0.79	9.4	10.90	12.3	19	0.36	1.18	-2.5	0.33	2.1
	Week 20	19	11.01	0.92	9.8	10.90	13.4	19	0.36	1.13	-1.9	0.40	2.9
	Week 22	19	10.93	0.87	9.9	10.80	13.4	19	0.28	1.07	-1.7	0.43	3.0
	Week 24	19	10.66	0.96	9.3	10.50	12.3	19	0.01	1.00	-1.8	0.13	1.4
	Week 26	19	10.67	1.14	8.4	10.70	12.4	19	0.02	1.13	-1.9	0.00	1.9
	Week 28	19	10.51	1.13	8.6	10.20	12.8	19	-0.14	1.19	-2.1	0.07	2.4
	Week 30	19	10.76	0.97	9.1	10.80	12.5	19	0.11	1.03	-1.7	0.23	2.1
	Week 32	19	10.58	0.72	9.1	10.70	11.9	19	-0.07	0.65	-1.3	-0.30	1.1
	Week 33	19	10.72	0.57	9.6	10.70	11.7	19	0.07	0.73	-1.7	0.03	1.7
	Week 34	19	10.74	0.62	9.8	10.50	12.0	19	0.09	0.81	-1.5	-0.03	1.8
	Week 35	19	10.73	0.76	9.7	10.50	12.6	19	0.08	1.02	-1.6	0.13	2.6
	Week 36	19	10.82	0.86	9.6	10.60	12.7	19	0.17	1.11	-1.8	0.13	2.7
	Week 38	19	10.85	0.89	9.5	10.60	12.7	19	0.20	1.18	-1.9	0.03	2.7
	Week 40	19	10.84	0.93	9.4	10.80	12.4	19	0.19	1.24	-1.6	0.03	2.8
	Week 42	19	10.74	0.86	9.0	10.90	12.1	19	0.09	1.04	-1.3	-0.10	2.5
	Week 44	19	10.89	0.96	8.9	10.90	12.6	19	0.24	1.18	-2.0	0.20	2.5
	Week 46	19	10.93	0.71	9.4	11.00	11.8	19	0.28	0.81	-1.4	0.40	1.5
	Week 48	19	11.02	0.79	9.4	11.30	12.3	19	0.37	0.86	-1.5	0.90	1.3
	Week 50	19	11.01	0.58	9.7	10.90	12.0	19	0.36	0.66	-0.9	0.37	1.5
	Week 52	19	10.97	0.71	9.8	11.10	12.6	19	0.32	0.71	-1.2	0.20	1.4
	Evaluation period	20	10.77	0.60	10.0	10.58	12.2	20	0.07	0.84	-1.4	0.11	2.2
	End of Follow-Up	20	10.43	0.93	8.7	10.35	11.8	20	-0.28	0.95	-1.9	-0.38	1.5

The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)


		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Molidustat (N=23)	Screening -3	2	10.95	0.21	10.8	10.95	11.1						
	Screening -2	23	10.83	0.57	10.0	10.80	12.0						
	Screening -1	23	10.69	0.65	9.2	10.60	12.0						
	Week 0	23	10.63	0.60	9.3	10.50	11.8						
	Baseline	23	10.73	0.54	9.5	10.60	11.8						
	Week 2	23	10.16	0.76	8.5	10.30	11.2	23	-0.57	0.57	-2.1	-0.60	0.7
	Week 4	23	9.74	1.00	7.3	9.80	11.4	23	-0.99	0.88	-3.3	-1.05	0.8
	Week 6	23	9.77	1.13	7.5	9.90	11.9	23	-0.95	1.10	-3.1	-1.20	1.4
	Week 8	21	9.92	1.21	7.5	9.90	12.8	21	-0.81	1.16	-2.4	-1.15	2.3
	Week 10	21	10.02	1.30	7.8	9.90	12.1	21	-0.71	1.31	-2.9	-0.80	1.6
	Week 12	20	10.32	1.41	8.1	10.10	13.2	20	-0.36	1.39	-2.6	-0.53	2.7
	Week 14	20	10.38	1.37	8.3	10.05	12.6	20	-0.30	1.34	-2.9	-0.50	1.9
	Week 16	20	10.59	1.30	8.1	10.50	12.6	20	-0.09	1.38	-3.5	-0.05	2.4
	Week 18	20	10.57	1.17	8.3	10.90	12.5	20	-0.11	1.29	-3.3	0.27	2.3
	Week 20	20	10.90	1.08	8.7	11.15	12.7	20	0.22	1.21	-2.9	0.47	2.5
	Week 22	19	11.01	1.18	8.6	11.30	13.5	19	0.32	1.37	-3.0	0.20	3.1
	Week 24	19	10.90	1.19	8.2	11.20	13.3	19	0.22	1.34	-3.4	0.20	2.9
	Week 26	19	10.91	1.02	9.1	11.40	12.5	19	0.22	1.12	-2.3	0.40	2.1
	Week 28	18	10.86	1.08	8.9	11.10	12.8	18	0.19	1.16	-2.7	0.33	1.6
	Week 30	18	10.76	0.99	8.9	11.10	12.3	18	0.09	1.24	-2.7	0.20	2.7
	Week 32	18	10.87	1.04	9.4	11.20	12.5	18	0.19	1.19	-2.2	0.70	1.7
	Week 33	18	10.92	0.99	9.6	11.15	12.4	18	0.24	1.13	-2.0	0.70	1.7
	Week 34	18	10.86	0.91	8.9	11.05	12.1	18	0.18	1.12	-2.2	0.52	1.6
	Week 35	18	10.94	0.97	8.9	11.25	12.0	18	0.27	1.16	-2.2	0.78	1.6
	Week 36	18	10.92	0.85	9.0	10.90	12.1	18	0.25	1.04	-2.1	0.30	1.7
	Week 38	18	10.74	0.94	8.7	10.90	12.1	18	0.07	1.18	-2.4	0.33	1.7
	Week 40	18	10.84	1.19	7.8	10.90	12.8	18	0.17	1.41	-3.3	0.33	2.4
	Week 42	17	11.04	0.98	9.6	11.00	13.3	17	0.39	1.21	-1.4	0.07	2.9
	Week 44	17	10.96	0.97	9.4	10.80	12.7	17	0.32	1.20	-1.4	-0.17	2.3
	Week 46	16	11.00	0.77	9.7	11.10	12.1	16	0.36	1.00	-0.8	-0.03	1.7
	Week 48	15	10.82	0.72	9.8	10.90	11.9	15	0.11	0.88	-1.2	-0.33	1.6
	Week 50	15	11.01	0.59	9.9	10.90	12.2	15	0.29	0.70	-0.7	0.30	1.8
	Week 52	15	10.70	0.83	9.4	10.70	12.3	15	-0.01	0.91	-1.1	-0.17	1.9
	Evaluation period	23	10.22	1.74	4.8	10.50	12.1	23	-0.51	1.90	-6.1	-0.05	1.6
	End of Follow-Up	23	10.55	1.53	7.6	10.80	12.9	23	-0.18	1.64	-2.8	0.33	2.1

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: High (> 3000.000 IU/week)

		Value at visit						Change from Baseline					
Planned Treatment	Visit	n	Mean	SD	Min	Median	Max	n	Mean	SD	Min	Median	Max
Darbepoetin alfa (N=12)	Screening -3	1	11.50	.	11.5	11.50	11.5						
	Screening -2	12	10.74	0.55	9.9	10.75	11.8						
	Screening -1	12	10.59	0.63	9.3	10.50	11.8						
	Week 0	12	10.53	0.98	9.2	10.30	12.8						
	Baseline	12	10.61	0.62	9.5	10.43	11.9						
	Week 2	11	10.71	1.05	9.3	10.60	13.1	11	0.07	0.55	-1.0	-0.07	1.2
	Week 4	11	10.54	0.63	9.8	10.50	11.9	11	-0.10	0.26	-0.5	-0.03	0.3
	Week 6	11	10.63	0.65	9.6	10.60	12.0	11	-0.01	0.54	-0.7	-0.03	1.1
	Week 8	11	10.86	0.54	10.2	10.70	11.9	11	0.23	0.70	-0.7	0.03	1.9
	Week 10	11	10.90	0.53	10.3	10.80	12.0	11	0.26	0.63	-1.0	0.33	1.2
	Week 12	11	10.81	0.52	9.7	10.90	11.5	11	0.17	0.84	-1.6	0.23	1.7
	Week 14	11	10.92	0.73	9.2	11.10	11.9	11	0.28	0.94	-2.1	0.37	1.6
	Week 16	11	10.99	0.90	8.7	11.00	12.4	11	0.35	1.19	-2.6	0.50	2.0
	Week 18	11	11.05	0.89	8.7	11.30	12.3	11	0.41	1.21	-2.6	0.60	2.1
	Week 20	11	10.82	1.30	8.4	10.80	12.8	11	0.18	1.53	-2.5	0.57	1.8
	Week 22	11	10.85	1.12	9.0	10.90	12.4	11	0.22	1.25	-2.2	0.47	1.9
	Week 24	11	10.68	1.03	8.6	10.80	12.0	11	0.04	1.20	-2.7	0.40	1.3
	Week 26	11	10.56	0.83	9.0	10.80	11.9	11	-0.07	0.98	-1.6	0.10	1.3
	Week 28	11	10.58	0.79	9.3	10.90	11.7	11	-0.06	0.93	-2.0	0.13	0.9
	Week 30	10	10.36	0.52	9.1	10.40	11.0	10	-0.23	0.84	-1.5	0.02	1.0
	Week 32	10	10.36	0.59	9.2	10.20	11.4	10	-0.23	0.86	-1.8	-0.13	1.1
	Week 33	9	10.56	0.56	9.9	10.60	11.4	9	-0.06	0.96	-1.9	0.03	1.6
	Week 34	9	10.53	0.68	9.7	10.40	11.7	9	-0.08	1.03	-2.2	-0.17	1.6
	Week 35	9	10.67	0.65	9.7	10.60	11.7	9	0.05	0.95	-1.9	0.07	1.6
	Week 36	9	10.59	0.62	9.9	10.30	11.5	9	-0.03	0.98	-2.0	-0.10	1.6
	Week 38	9	10.79	0.52	10.2	10.60	11.8	9	0.17	0.83	-1.7	0.20	1.5
	Week 40	9	10.60	0.66	9.8	10.50	11.9	9	-0.02	0.99	-2.1	0.07	1.6
	Week 42	9	10.62	0.66	9.6	10.60	11.8	9	0.01	1.04	-2.3	0.00	1.4
	Week 44	9	10.64	0.65	10.0	10.30	11.8	9	0.03	0.80	-1.8	0.23	0.8
	Week 46	9	10.44	0.68	9.6	10.20	11.4	9	-0.17	0.86	-1.4	-0.10	0.8
	Week 48	9	10.43	0.97	9.4	10.00	12.5	9	-0.18	0.82	-1.9	0.07	0.7
	Week 50	9	10.69	0.82	9.5	10.40	11.9	9	0.07	0.82	-1.2	0.03	1.5
	Week 52	9	10.53	0.70	9.6	10.40	12.0	9	-0.08	0.73	-1.7	0.10	0.8
	Evaluation period	12	10.39	0.81	9.0	10.43	11.6	12	-0.22	0.95	-2.0	0.00	1.6
	End of Follow-Up	12	10.08	0.95	8.2	10.20	11.7	12	-0.53	0.69	-2.1	-0.43	0.4


The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
Screening - X: the Xth last Hb level of scheduled visit during screening period

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL


Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total
Planned Treatment: Darbepoetin alfa



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

図 2.7.3.6-34 前治療として使用した ESA の種類別（DA、PEGOL 又は rHuEPO）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

表 2.7.3.6-75 前治療として使用した ESA の種類別（DA、PEGOL 又は rHuEPO）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Visit	Hb Level	Molidustat (N=86)	Darbepoetin alfa (N=35)
Baseline	n	86	35
	Below	9 (10.5%)	2 (5.7%)
	In	77 (89.5%)	33 (94.3%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	84	35
	Below	19 (22.6%)	2 (5.7%)
	In	61 (72.6%)	31 (88.6%)
	Above	4 (4.8%)	2 (5.7%)
Week 4	n	83	34
	Below	27 (32.5%)	2 (5.9%)
	In	50 (60.2%)	29 (85.3%)
	Above	6 (7.2%)	3 (8.8%)
Week 6	n	81	34
	Below	32 (39.5%)	4 (11.8%)
	In	42 (51.9%)	25 (73.5%)
	Above	7 (8.6%)	5 (14.7%)
Week 8	n	78	33
	Below	29 (37.2%)	3 (9.1%)
	In	42 (53.8%)	28 (84.8%)
	Above	7 (9.0%)	2 (6.1%)
Week 10	n	76	33
	Below	24 (31.6%)	5 (15.2%)
	In	42 (55.3%)	26 (78.8%)
	Above	10 (13.2%)	2 (6.1%)
Week 12	n	75	33
	Below	25 (33.3%)	5 (15.2%)
	In	39 (52.0%)	26 (78.8%)
	Above	11 (14.7%)	2 (6.1%)
Week 14	n	71	31
	Below	18 (25.4%)	3 (9.7%)
	In	41 (57.7%)	26 (83.9%)
	Above	12 (16.9%)	2 (6.5%)
Week 16	n	70	31
	Below	16 (22.9%)	5 (16.1%)
	In	37 (52.9%)	24 (77.4%)
	Above	17 (24.3%)	2 (6.5%)
Week 18	n	69	30
	Below	8 (11.6%)	3 (10.0%)
	In	45 (65.2%)	23 (76.7%)
	Above	16 (23.2%)	4 (13.3%)
Week 20	n	69	31
	Below	8 (11.6%)	3 (9.7%)
	In	48 (69.6%)	27 (87.1%)
	Above	13 (18.8%)	1 (3.2%)
Week 22	n	69	31
	Below	3 (4.3%)	4 (12.9%)
	In	54 (78.3%)	27 (87.1%)
	Above	12 (17.4%)	0 (0.0%)
Week 24	n	67	31
	Below	5 (7.5%)	6 (19.4%)
	In	48 (71.6%)	22 (71.0%)
	Above	14 (20.9%)	3 (9.7%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Visit	Hb Level	Molidustat (N=86)	Darbepoetin alfa (N=35)
Week 26	n	69	31
	Below	7 (10.1%)	3 (9.7%)
	In	45 (65.2%)	27 (87.1%)
	Above	17 (24.6%)	1 (3.2%)
Week 28	n	68	31
	Below	5 (7.4%)	2 (6.5%)
	In	48 (70.6%)	27 (87.1%)
	Above	15 (22.1%)	2 (6.5%)
Week 30	n	67	31
	Below	4 (6.0%)	2 (6.5%)
	In	54 (80.6%)	27 (87.1%)
	Above	9 (13.4%)	2 (6.5%)
Week 32	n	67	31
	Below	8 (11.9%)	1 (3.2%)
	In	51 (76.1%)	27 (87.1%)
	Above	8 (11.9%)	3 (9.7%)
Week 33	n	66	31
	Below	6 (9.1%)	3 (9.7%)
	In	47 (71.2%)	24 (77.4%)
	Above	13 (19.7%)	4 (12.9%)
Week 34	n	66	31
	Below	8 (12.1%)	2 (6.5%)
	In	47 (71.2%)	26 (83.9%)
	Above	11 (16.7%)	3 (9.7%)
Week 35	n	66	31
	Below	11 (16.7%)	2 (6.5%)
	In	48 (72.7%)	26 (83.9%)
	Above	7 (10.6%)	3 (9.7%)
Week 36	n	65	31
	Below	12 (18.5%)	2 (6.5%)
	In	47 (72.3%)	26 (83.9%)
	Above	6 (9.2%)	3 (9.7%)
Week 38	n	66	31
	Below	8 (12.1%)	3 (9.7%)
	In	51 (77.3%)	26 (83.9%)
	Above	7 (10.6%)	2 (6.5%)
Week 40	n	65	31
	Below	7 (10.8%)	7 (22.6%)
	In	52 (80.0%)	22 (71.0%)
	Above	6 (9.2%)	2 (6.5%)
Week 42	n	62	31
	Below	10 (16.1%)	7 (22.6%)
	In	47 (75.8%)	20 (64.5%)
	Above	5 (8.1%)	4 (12.9%)
Week 44	n	61	31
	Below	5 (8.2%)	5 (16.1%)
	In	48 (78.7%)	23 (74.2%)
	Above	8 (13.1%)	3 (9.7%)
Week 46	n	61	31
	Below	5 (8.2%)	6 (19.4%)
	In	47 (77.0%)	23 (74.2%)
	Above	9 (14.8%)	2 (6.5%)
Week 48	n	61	31
	Below	9 (14.8%)	7 (22.6%)
	In	45 (73.8%)	21 (67.7%)
	Above	7 (11.5%)	3 (9.7%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Total

Visit	Hb Level	Molidustat (N=86)	Darbepoetin alfa (N=35)
Week 50	n	61	30
	Below	7 (11.5%)	3 (10.0%)
	In	45 (73.8%)	26 (86.7%)
	Above	9 (14.8%)	1 (3.3%)
Week 52	n	61	29
	Below	7 (11.5%)	4 (13.8%)
	In	44 (72.1%)	24 (82.8%)
	Above	10 (16.4%)	1 (3.4%)
Evaluation period	n	86	35
	Below	19 (22.1%)	3 (8.6%)
	In	57 (66.3%)	28 (80.0%)
	Above	10 (11.6%)	4 (11.4%)
End of Follow-Up	n	84	33
	Below	20 (23.8%)	6 (18.2%)
	In	59 (70.2%)	25 (75.8%)
	Above	5 (6.0%)	2 (6.1%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Visit	Hb Level	Molidustat (N=19)	Darbepoetin alfa (N=9)
Baseline	n	19	9
	Below	3 (15.8%)	1 (11.1%)
	In	16 (84.2%)	8 (88.9%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	19	8
	Below	3 (15.8%)	2 (25.0%)
	In	13 (68.4%)	5 (62.5%)
	Above	3 (15.8%)	1 (12.5%)
Week 4	n	19	8
	Below	4 (21.1%)	2 (25.0%)
	In	13 (68.4%)	5 (62.5%)
	Above	2 (10.5%)	1 (12.5%)
Week 6	n	19	8
	Below	2 (10.5%)	1 (12.5%)
	In	14 (73.7%)	5 (62.5%)
	Above	3 (15.8%)	2 (25.0%)
Week 8	n	19	8
	Below	3 (15.8%)	1 (12.5%)
	In	11 (57.9%)	6 (75.0%)
	Above	5 (26.3%)	1 (12.5%)
Week 10	n	19	8
	Below	4 (21.1%)	2 (25.0%)
	In	11 (57.9%)	6 (75.0%)
	Above	4 (21.1%)	0 (0.0%)
Week 12	n	19	8
	Below	3 (15.8%)	1 (12.5%)
	In	9 (47.4%)	7 (87.5%)
	Above	7 (36.8%)	0 (0.0%)
Week 14	n	19	8
	Below	4 (21.1%)	1 (12.5%)
	In	6 (31.6%)	7 (87.5%)
	Above	9 (47.4%)	0 (0.0%)
Week 16	n	19	8
	Below	3 (15.8%)	2 (25.0%)
	In	6 (31.6%)	6 (75.0%)
	Above	10 (52.6%)	0 (0.0%)
Week 18	n	19	8
	Below	4 (21.1%)	1 (12.5%)
	In	8 (42.1%)	6 (75.0%)
	Above	7 (36.8%)	1 (12.5%)
Week 20	n	19	8
	Below	2 (10.5%)	1 (12.5%)
	In	11 (57.9%)	7 (87.5%)
	Above	6 (31.6%)	0 (0.0%)
Week 22	n	19	8
	Below	4 (21.1%)	1 (12.5%)
	In	14 (73.7%)	7 (87.5%)
	Above	1 (5.3%)	0 (0.0%)
Week 24	n	19	8
	Below	4 (21.1%)	2 (25.0%)
	In	10 (52.6%)	6 (75.0%)
	Above	5 (26.3%)	0 (0.0%)
Week 26	n	19	8
	Below	3 (15.8%)	2 (25.0%)
	In	10 (52.6%)	6 (75.0%)
	Above	6 (31.6%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Visit	Hb Level	Molidustat (N=19)	Darbepoetin alfa (N=9)
Week 28	n	19	8
	Below	3 (15.8%)	1 (12.5%)
	In	12 (63.2%)	7 (87.5%)
	Above	4 (21.1%)	0 (0.0%)
Week 30	n	19	8
	Below	2 (10.5%)	1 (12.5%)
	In	13 (68.4%)	7 (87.5%)
	Above	4 (21.1%)	0 (0.0%)
Week 32	n	19	8
	Below	3 (15.8%)	2 (25.0%)
	In	11 (57.9%)	5 (62.5%)
	Above	5 (26.3%)	1 (12.5%)
Week 33	n	19	8
	Below	3 (15.8%)	1 (12.5%)
	In	11 (57.9%)	5 (62.5%)
	Above	5 (26.3%)	2 (25.0%)
Week 34	n	19	8
	Below	3 (15.8%)	2 (25.0%)
	In	12 (63.2%)	4 (50.0%)
	Above	4 (21.1%)	2 (25.0%)
Week 35	n	19	8
	Below	1 (5.3%)	1 (12.5%)
	In	13 (68.4%)	6 (75.0%)
	Above	5 (26.3%)	1 (12.5%)
Week 36	n	19	8
	Below	2 (10.5%)	0 (0.0%)
	In	13 (68.4%)	8 (100.0%)
	Above	4 (21.1%)	0 (0.0%)
Week 38	n	19	8
	Below	1 (5.3%)	0 (0.0%)
	In	14 (73.7%)	7 (87.5%)
	Above	4 (21.1%)	1 (12.5%)
Week 40	n	19	8
	Below	2 (10.5%)	0 (0.0%)
	In	15 (78.9%)	6 (75.0%)
	Above	2 (10.5%)	2 (25.0%)
Week 42	n	19	8
	Below	0 (0.0%)	1 (12.5%)
	In	14 (73.7%)	7 (87.5%)
	Above	5 (26.3%)	0 (0.0%)
Week 44	n	19	8
	Below	0 (0.0%)	2 (25.0%)
	In	15 (78.9%)	6 (75.0%)
	Above	4 (21.1%)	0 (0.0%)
Week 46	n	19	8
	Below	1 (5.3%)	2 (25.0%)
	In	14 (73.7%)	5 (62.5%)
	Above	4 (21.1%)	1 (12.5%)
Week 48	n	19	8
	Below	0 (0.0%)	1 (12.5%)
	In	14 (73.7%)	6 (75.0%)
	Above	5 (26.3%)	1 (12.5%)
Week 50	n	19	8
	Below	1 (5.3%)	1 (12.5%)
	In	14 (73.7%)	7 (87.5%)
	Above	4 (21.1%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin beta pegol
Categories: Total

Visit	Hb Level	Molidustat (N=19)	Darbepoetin alfa (N=9)
Week 52	n	19	8
	Below	2 (10.5%)	1 (12.5%)
	In	13 (68.4%)	7 (87.5%)
	Above	4 (21.1%)	0 (0.0%)
Evaluation period	n	19	9
	Below	2 (10.5%)	2 (22.2%)
	In	13 (68.4%)	5 (55.6%)
	Above	4 (21.1%)	2 (22.2%)
End of Follow-Up	n	19	9
	Below	4 (21.1%)	2 (22.2%)
	In	10 (52.6%)	6 (66.7%)
	Above	5 (26.3%)	1 (11.1%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

Visit	Hb Level	Molidustat (N=48)	Darbepoetin alfa (N=32)
Baseline	n	48	32
	Below	4 (8.3%)	3 (9.4%)
	In	44 (91.7%)	29 (90.6%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	48	31
	Below	15 (31.3%)	2 (6.5%)
	In	31 (64.6%)	28 (90.3%)
	Above	2 (4.2%)	1 (3.2%)
Week 4	n	47	30
	Below	18 (38.3%)	2 (6.7%)
	In	25 (53.2%)	28 (93.3%)
	Above	4 (8.5%)	0 (0.0%)
Week 6	n	47	30
	Below	17 (36.2%)	2 (6.7%)
	In	25 (53.2%)	25 (83.3%)
	Above	5 (10.6%)	3 (10.0%)
Week 8	n	42	30
	Below	15 (35.7%)	0 (0.0%)
	In	20 (47.6%)	29 (96.7%)
	Above	7 (16.7%)	1 (3.3%)
Week 10	n	43	30
	Below	16 (37.2%)	0 (0.0%)
	In	17 (39.5%)	28 (93.3%)
	Above	10 (23.3%)	2 (6.7%)
Week 12	n	41	30
	Below	11 (26.8%)	1 (3.3%)
	In	19 (46.3%)	26 (86.7%)
	Above	11 (26.8%)	3 (10.0%)
Week 14	n	41	30
	Below	10 (24.4%)	2 (6.7%)
	In	19 (46.3%)	24 (80.0%)
	Above	12 (29.3%)	4 (13.3%)
Week 16	n	41	30
	Below	9 (22.0%)	2 (6.7%)
	In	23 (56.1%)	24 (80.0%)
	Above	9 (22.0%)	4 (13.3%)
Week 18	n	41	30
	Below	8 (19.5%)	3 (10.0%)
	In	26 (63.4%)	23 (76.7%)
	Above	7 (17.1%)	4 (13.3%)
Week 20	n	41	30
	Below	5 (12.2%)	3 (10.0%)
	In	31 (75.6%)	22 (73.3%)
	Above	5 (12.2%)	5 (16.7%)
Week 22	n	40	30
	Below	6 (15.0%)	3 (10.0%)
	In	30 (75.0%)	23 (76.7%)
	Above	4 (10.0%)	4 (13.3%)
Week 24	n	40	30
	Below	6 (15.0%)	8 (26.7%)
	In	31 (77.5%)	20 (66.7%)
	Above	3 (7.5%)	2 (6.7%)
Week 26	n	39	30
	Below	6 (15.4%)	7 (23.3%)
	In	26 (66.7%)	19 (63.3%)
	Above	7 (17.9%)	4 (13.3%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total


Visit	Hb Level	Molidustat (N=48)	Darbepoetin alfa (N=32)
Week 28	n	38	30
	Below	6 (15.8%)	8 (26.7%)
	In	28 (73.7%)	19 (63.3%)
	Above	4 (10.5%)	3 (10.0%)
Week 30	n	37	29
	Below	8 (21.6%)	5 (17.2%)
	In	25 (67.6%)	22 (75.9%)
	Above	4 (10.8%)	2 (6.9%)
Week 32	n	38	29
	Below	7 (18.4%)	5 (17.2%)
	In	25 (65.8%)	24 (82.8%)
	Above	6 (15.8%)	0 (0.0%)
Week 33	n	37	28
	Below	7 (18.9%)	3 (10.7%)
	In	23 (62.2%)	25 (89.3%)
	Above	7 (18.9%)	0 (0.0%)
Week 34	n	37	28
	Below	7 (18.9%)	3 (10.7%)
	In	27 (73.0%)	24 (85.7%)
	Above	3 (8.1%)	1 (3.6%)
Week 35	n	37	28
	Below	8 (21.6%)	3 (10.7%)
	In	24 (64.9%)	24 (85.7%)
	Above	5 (13.5%)	1 (3.6%)
Week 36	n	37	28
	Below	5 (13.5%)	2 (7.1%)
	In	28 (75.7%)	24 (85.7%)
	Above	4 (10.8%)	2 (7.1%)
Week 38	n	37	28
	Below	5 (13.5%)	3 (10.7%)
	In	27 (73.0%)	22 (78.6%)
	Above	5 (13.5%)	3 (10.7%)
Week 40	n	37	28
	Below	6 (16.2%)	5 (17.9%)
	In	26 (70.3%)	19 (67.9%)
	Above	5 (13.5%)	4 (14.3%)
Week 42	n	36	28
	Below	2 (5.6%)	6 (21.4%)
	In	30 (83.3%)	21 (75.0%)
	Above	4 (11.1%)	1 (3.6%)
Week 44	n	36	28
	Below	5 (13.9%)	3 (10.7%)
	In	24 (66.7%)	23 (82.1%)
	Above	7 (19.4%)	2 (7.1%)
Week 46	n	35	28
	Below	3 (8.6%)	6 (21.4%)
	In	26 (74.3%)	22 (78.6%)
	Above	6 (17.1%)	0 (0.0%)
Week 48	n	34	28
	Below	3 (8.8%)	7 (25.0%)
	In	29 (85.3%)	19 (67.9%)
	Above	2 (5.9%)	2 (7.1%)
Week 50	n	34	28
	Below	1 (2.9%)	2 (7.1%)
	In	29 (85.3%)	25 (89.3%)
	Above	4 (11.8%)	1 (3.6%)

Last Erythropoiesis-Stimulating Agent treatment: Epoetin alfa or beta
Categories: Total

Visit	Hb Level	Molidustat (N=48)	Darbepoetin alfa (N=32)
Week 52	n	34	28
	Below	3 (8.8%)	3 (10.7%)
	In	28 (82.4%)	22 (78.6%)
	Above	3 (8.8%)	3 (10.7%)
Evaluation period	n	48	32
	Below	16 (33.3%)	4 (12.5%)
	In	30 (62.5%)	27 (84.4%)
	Above	2 (4.2%)	1 (3.1%)
End of Follow-Up	n	48	32
	Below	12 (25.0%)	12 (37.5%)
	In	28 (58.3%)	20 (62.5%)
	Above	8 (16.7%)	0 (0.0%)


The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.00 ug/week)
Planned Treatment: Molidustat




The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL


Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.00 ug/week)
Planned Treatment: Molidustat



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL



The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0
The target range >= 10.0 and < 12.0 g/dL

図 2.7.3.6-35 前治療として使用した DA の用量別（中央値以下又は中央値超別）の各来院時の Hb 値が目標 Hb 値内、上限以上又は下限未満に該当する被験者の割合（試験 19352、FAS）

表 2.7.3.6-76 前治療として使用したDAの用量別（中央値以下又は中央値超別）の各来院時のHb値が目標Hb値内、上限以上又は下限未満に該当する被験者の割合（試験19352、FAS）

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

Visit	Hb Level	Molidustat (N=51)	Darbepoetin alfa (N=18)
Baseline	n	51	18
	Below	2 (3.9%)	0 (0.0%)
	In	49 (96.1%)	18 (100.0%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	50	18
	Below	10 (20.0%)	0 (0.0%)
	In	37 (74.0%)	17 (94.4%)
	Above	3 (6.0%)	1 (5.6%)
Week 4	n	50	18
	Below	16 (32.0%)	1 (5.6%)
	In	29 (58.0%)	15 (83.3%)
	Above	5 (10.0%)	2 (11.1%)
Week 6	n	49	18
	Below	18 (36.7%)	1 (5.6%)
	In	26 (53.1%)	14 (77.8%)
	Above	5 (10.2%)	3 (16.7%)
Week 8	n	49	17
	Below	16 (32.7%)	2 (11.8%)
	In	28 (57.1%)	15 (88.2%)
	Above	5 (10.2%)	0 (0.0%)
Week 10	n	48	17
	Below	12 (25.0%)	2 (11.8%)
	In	28 (58.3%)	14 (82.4%)
	Above	8 (16.7%)	1 (5.9%)
Week 12	n	48	17
	Below	13 (27.1%)	3 (17.6%)
	In	26 (54.2%)	14 (82.4%)
	Above	9 (18.8%)	0 (0.0%)
Week 14	n	44	17
	Below	9 (20.5%)	2 (11.8%)
	In	26 (59.1%)	14 (82.4%)
	Above	9 (20.5%)	1 (5.9%)
Week 16	n	44	17
	Below	6 (13.6%)	3 (17.6%)
	In	27 (61.4%)	14 (82.4%)
	Above	11 (25.0%)	0 (0.0%)
Week 18	n	43	16
	Below	3 (7.0%)	1 (6.3%)
	In	29 (67.4%)	14 (87.5%)
	Above	11 (25.6%)	1 (6.3%)
Week 20	n	43	17
	Below	3 (7.0%)	1 (5.9%)
	In	33 (76.7%)	16 (94.1%)
	Above	7 (16.3%)	0 (0.0%)
Week 22	n	43	17
	Below	1 (2.3%)	0 (0.0%)
	In	35 (81.4%)	17 (100.0%)
	Above	7 (16.3%)	0 (0.0%)
Week 24	n	41	17
	Below	2 (4.9%)	3 (17.6%)
	In	32 (78.0%)	12 (70.6%)
	Above	7 (17.1%)	2 (11.8%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

Visit	Hb Level	Molidustat (N=51)	Darbepoetin alfa (N=18)
Week 26	n	43	17
	Below	3 (7.0%)	1 (5.9%)
	In	28 (65.1%)	15 (88.2%)
	Above	12 (27.9%)	1 (5.9%)
Week 28	n	42	17
	Below	2 (4.8%)	1 (5.9%)
	In	31 (73.8%)	15 (88.2%)
	Above	9 (21.4%)	1 (5.9%)
Week 30	n	42	17
	Below	2 (4.8%)	2 (11.8%)
	In	33 (78.6%)	14 (82.4%)
	Above	7 (16.7%)	1 (5.9%)
Week 32	n	42	17
	Below	5 (11.9%)	1 (5.9%)
	In	30 (71.4%)	15 (88.2%)
	Above	7 (16.7%)	1 (5.9%)
Week 33	n	41	17
	Below	2 (4.9%)	2 (11.8%)
	In	27 (65.9%)	14 (82.4%)
	Above	12 (29.3%)	1 (5.9%)
Week 34	n	41	17
	Below	5 (12.2%)	2 (11.8%)
	In	27 (65.9%)	15 (88.2%)
	Above	9 (22.0%)	0 (0.0%)
Week 35	n	41	17
	Below	5 (12.2%)	2 (11.8%)
	In	29 (70.7%)	14 (82.4%)
	Above	7 (17.1%)	1 (5.9%)
Week 36	n	40	17
	Below	5 (12.5%)	2 (11.8%)
	In	29 (72.5%)	14 (82.4%)
	Above	6 (15.0%)	1 (5.9%)
Week 38	n	41	17
	Below	3 (7.3%)	2 (11.8%)
	In	33 (80.5%)	14 (82.4%)
	Above	5 (12.2%)	1 (5.9%)
Week 40	n	40	17
	Below	4 (10.0%)	3 (17.6%)
	In	32 (80.0%)	12 (70.6%)
	Above	4 (10.0%)	2 (11.8%)
Week 42	n	40	17
	Below	4 (10.0%)	3 (17.6%)
	In	33 (82.5%)	11 (64.7%)
	Above	3 (7.5%)	3 (17.6%)
Week 44	n	39	17
	Below	2 (5.1%)	3 (17.6%)
	In	33 (84.6%)	12 (70.6%)
	Above	4 (10.3%)	2 (11.8%)
Week 46	n	39	17
	Below	3 (7.7%)	4 (23.5%)
	In	30 (76.9%)	11 (64.7%)
	Above	6 (15.4%)	2 (11.8%)
Week 48	n	39	17
	Below	6 (15.4%)	5 (29.4%)
	In	28 (71.8%)	10 (58.8%)
	Above	5 (12.8%)	2 (11.8%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: Low (<= 15.000 ug/week)

Visit	Hb Level	Molidustat (N=51)	Darbepoetin alfa (N=18)
Week 50	n	39	16
	Below	3 (7.7%)	2 (12.5%)
	In	30 (76.9%)	13 (81.3%)
	Above	6 (15.4%)	1 (6.3%)
Week 52	n	39	15
	Below	3 (7.7%)	3 (20.0%)
	In	30 (76.9%)	12 (80.0%)
	Above	6 (15.4%)	0 (0.0%)
Evaluation period	n	51	18
	Below	8 (15.7%)	2 (11.1%)
	In	33 (64.7%)	14 (77.8%)
	Above	10 (19.6%)	2 (11.1%)
End of Follow-Up	n	50	17
	Below	10 (20.0%)	1 (5.9%)
	In	37 (74.0%)	15 (88.2%)
	Above	3 (6.0%)	1 (5.9%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

Visit	Hb Level	Molidustat (N=35)	Darbepoetin alfa (N=17)
Baseline	n	35	17
	Below	7 (20.0%)	2 (11.8%)
	In	28 (80.0%)	15 (88.2%)
	Above	0 (0.0%)	0 (0.0%)
Week 2	n	34	17
	Below	9 (26.5%)	2 (11.8%)
	In	24 (70.6%)	14 (82.4%)
	Above	1 (2.9%)	1 (5.9%)
Week 4	n	33	16
	Below	11 (33.3%)	1 (6.3%)
	In	21 (63.6%)	14 (87.5%)
	Above	1 (3.0%)	1 (6.3%)
Week 6	n	32	16
	Below	14 (43.8%)	3 (18.8%)
	In	16 (50.0%)	11 (68.8%)
	Above	2 (6.3%)	2 (12.5%)
Week 8	n	29	16
	Below	13 (44.8%)	1 (6.3%)
	In	14 (48.3%)	13 (81.3%)
	Above	2 (6.9%)	2 (12.5%)
Week 10	n	28	16
	Below	12 (42.9%)	3 (18.8%)
	In	14 (50.0%)	12 (75.0%)
	Above	2 (7.1%)	1 (6.3%)
Week 12	n	27	16
	Below	12 (44.4%)	2 (12.5%)
	In	13 (48.1%)	12 (75.0%)
	Above	2 (7.4%)	2 (12.5%)
Week 14	n	27	14
	Below	9 (33.3%)	1 (7.1%)
	In	15 (55.6%)	12 (85.7%)
	Above	3 (11.1%)	1 (7.1%)
Week 16	n	26	14
	Below	10 (38.5%)	2 (14.3%)
	In	10 (38.5%)	10 (71.4%)
	Above	6 (23.1%)	2 (14.3%)
Week 18	n	26	14
	Below	5 (19.2%)	2 (14.3%)
	In	16 (61.5%)	9 (64.3%)
	Above	5 (19.2%)	3 (21.4%)
Week 20	n	26	14
	Below	5 (19.2%)	2 (14.3%)
	In	15 (57.7%)	11 (78.6%)
	Above	6 (23.1%)	1 (7.1%)
Week 22	n	26	14
	Below	2 (7.7%)	4 (28.6%)
	In	19 (73.1%)	10 (71.4%)
	Above	5 (19.2%)	0 (0.0%)
Week 24	n	26	14
	Below	3 (11.5%)	3 (21.4%)
	In	16 (61.5%)	10 (71.4%)
	Above	7 (26.9%)	1 (7.1%)
Week 26	n	26	14
	Below	4 (15.4%)	2 (14.3%)
	In	17 (65.4%)	12 (85.7%)
	Above	5 (19.2%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

Visit	Hb Level	Molidustat (N=35)	Darbepoetin alfa (N=17)
Week 28	n	26	14
	Below	3 (11.5%)	1 (7.1%)
	In	17 (65.4%)	12 (85.7%)
	Above	6 (23.1%)	1 (7.1%)
Week 30	n	25	14
	Below	2 (8.0%)	0 (0.0%)
	In	21 (84.0%)	13 (92.9%)
	Above	2 (8.0%)	1 (7.1%)
Week 32	n	25	14
	Below	3 (12.0%)	0 (0.0%)
	In	21 (84.0%)	12 (85.7%)
	Above	1 (4.0%)	2 (14.3%)
Week 33	n	25	14
	Below	4 (16.0%)	1 (7.1%)
	In	20 (80.0%)	10 (71.4%)
	Above	1 (4.0%)	3 (21.4%)
Week 34	n	25	14
	Below	3 (12.0%)	0 (0.0%)
	In	20 (80.0%)	11 (78.6%)
	Above	2 (8.0%)	3 (21.4%)
Week 35	n	25	14
	Below	6 (24.0%)	0 (0.0%)
	In	19 (76.0%)	12 (85.7%)
	Above	0 (0.0%)	2 (14.3%)
Week 36	n	25	14
	Below	7 (28.0%)	0 (0.0%)
	In	18 (72.0%)	12 (85.7%)
	Above	0 (0.0%)	2 (14.3%)
Week 38	n	25	14
	Below	5 (20.0%)	1 (7.1%)
	In	18 (72.0%)	12 (85.7%)
	Above	2 (8.0%)	1 (7.1%)
Week 40	n	25	14
	Below	3 (12.0%)	4 (28.6%)
	In	20 (80.0%)	10 (71.4%)
	Above	2 (8.0%)	0 (0.0%)
Week 42	n	22	14
	Below	6 (27.3%)	4 (28.6%)
	In	14 (63.6%)	9 (64.3%)
	Above	2 (9.1%)	1 (7.1%)
Week 44	n	22	14
	Below	3 (13.6%)	2 (14.3%)
	In	15 (68.2%)	11 (78.6%)
	Above	4 (18.2%)	1 (7.1%)
Week 46	n	22	14
	Below	2 (9.1%)	2 (14.3%)
	In	17 (77.3%)	12 (85.7%)
	Above	3 (13.6%)	0 (0.0%)
Week 48	n	22	14
	Below	3 (13.6%)	2 (14.3%)
	In	17 (77.3%)	11 (78.6%)
	Above	2 (9.1%)	1 (7.1%)
Week 50	n	22	14
	Below	4 (18.2%)	1 (7.1%)
	In	15 (68.2%)	13 (92.9%)
	Above	3 (13.6%)	0 (0.0%)

Last Erythropoiesis-Stimulating Agent treatment: Darbepoetin alfa
Categories: High (> 15.000 ug/week)

Visit	Hb Level	Molidustat (N=35)	Darbepoetin alfa (N=17)
Week 52	n	22	14
	Below	4 (18.2%)	1 (7.1%)
	In	14 (63.6%)	12 (85.7%)
	Above	4 (18.2%)	1 (7.1%)
Evaluation period	n	35	17
	Below	11 (31.4%)	1 (5.9%)
	In	24 (68.6%)	14 (82.4%)
	Above	0 (0.0%)	2 (11.8%)
End of Follow-Up	n	34	16
	Below	10 (29.4%)	5 (31.3%)
	In	22 (64.7%)	10 (62.5%)
	Above	2 (5.9%)	1 (6.3%)

The target range >= 10.0 and < 12.0 g/dL
n: The number of subjects who had a valid Hb level
The baseline Hb level is defined as the mean of all Hb levels during the screening period and Hb level at Week 0